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Human mutationMitochondrial ﬁssion and fusion have been observed, and their importance revealed, in almost every tissue
and cell type except adult cardiac myocytes. As each human heart is uniquely dependent upon mitochondria
to generate massive amounts of ATP that fuel its approximately 38 million contractions per year, it seems odd
that cardiac myocytes are the sole exception to the general rule that mitochondrial dynamism is important to
function. Here, I brieﬂy review the mechanisms for mitochondrial fusion and ﬁssion and examine current data
that dispel the previous notion that mitochondrial fusion is dispensable in the heart. Rare and generally over-
looked examples of cardiomyopathies linked either to naturally-occurring mutations or to experimentally-
induced mutagenesis of mitochondrial fusion/ﬁssion genes are described. New ﬁndings from genetically tar-
geted Drosophila and mouse models wherein mitochondrial fusion deﬁciency has speciﬁcally been induced in
cardiac myocytes are discussed. This article is part of a Special Issue entitled: Mitochondrial dynamics and
physiology.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Cardiologists like to point out that the heart is the hardest working
organ in the human body. It is widely reported that the human heart
consumes 30 kg of ATP per day fueling basal metabolism and normal
contraction that is essential to sustaining systemic and pulmonary
blood pressure [1]. Obviously, a ~300 g heart that daily consumes
100 times its weight in ATP does not do so by relying upon stored re-
serves, but must constantly be generating it. Almost all ATP is pro-
duced in cardiomyocyte mitochondria, with trivial amounts created
in the cytosol. Accordingly, ventricular myocardium is literally packed
full of mitochondria, which account for ~35% of cardiomyocyte vol-
ume [2]. There are more mitochondria in mammalian myocardium
than there are individual muscle sarcomeres (~2:1) (Fig. 1).
Mitochondrial ATP production is tightly regulated to meet varying
metabolic demands resulting from minute-by-minute (or Beat-to-
beat) changes in cardiac work. While the components of oxidative
phosphorylation and the electron transport chain are fully under-
stood, the molecular details of their regulatory pathways remain con-
troversial. Two major mechanisms have been proposed: Regulation
by ADP and inorganic phosphate (Pi) that are the products of ATP hy-
drolysis, and regulation by cytosolic calcium ([Ca2+]c) that is released
from the SR and sensed by the mitochondria in response to stimuli for
increased work. The former classical hypothesis [3] has been disputedMitochondrial dynamics and
ics, 660 S Euclid Ave., Campus
92; fax: +1 314 362 8844.
rights reserved.by Balaban and colleagues who found that large changes in cardiac
work and ATP consumption are not associated with measurable
changes in ADP/Pi levels [4,5], while the latter hypothesis has gained
credence from elegant studies of O'Rourke and coworkers [6,7]. It
seems likely that modulatory functions may exist for both ATP/ADP/
Pi and [Ca2+]c, the former playing a greater role regulating mitochon-
drial oxidative phosphorylation while the latter mainly affects Krebs
cycle dehydrogenases [8].
The unique bioenergetic requirements of the heart not only dictate
that it generate andmaintain the largest proportional density of mito-
chondria of any organ in the body, but that themitochondria are orga-
nized throughout the cardiac myocyte in a highly structured and
stable manner. As their names suggests, repeating ribbon-like clusters
of interﬁbrillar mitochondria run between myoﬁbrils arranged paral-
lel to the long axis of the cardiomyocyte. This enforced proximity of
mitochondria to sarcomeres throughout the cardiomyocyte provides
for a ready and continuous supply of ATP to all components of actin–
myosin contractile machinery. Similarly, deep T-tubular invaginations
of the cardiomyocyte plasma membrane (sarcolemma) inter-digitate
at close intervals into the myoﬁbrillar elements and mitochondrial
clusters. Synchronization of calcium entry throughout an electrically
depolarized cardiomyocyte is critical for harmoniously initiating
and terminating normal excitation–contraction coupling [9]. The T-
tubules facilitate coordinated calcium (Ca2+) import and export
throughout all parts of the cardiomyocyte simultaneously.
A third cellular organelle structure, the sarcoplasmic reticulum, like-
wise forms a continuous network that surrounds and permeates
myoﬁbrils and is intimately associatedwithmitochondrial clusters. Sar-
coplasmic reticulum (SR) is the primary calcium storage and release or-
ganelle for cardiomyocytes, and the source of the vast majority of the
Fig. 1. Subcellular arrangement of mitochondria in normal adult cardiomyocytes. Transmission electron micrograph of normal 8 week old mouse myocardium. Note lanes of interﬁ-
brillar mitochondria running between individual myoﬁbrils and cluster of mitochondria surrounding nucleus (bisected on right margin). The “sardines in a can”
arrangement appears to enforce inter-organelle contact and does not permit meaningful intra-cellular mitochondrial transport.
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lease is a passive process. In contrast, large amounts of ATP are required
to fuel SR Ca2+ reuptake via the SR Ca2+ ATPase (SERCA) that, together
with a smaller amount of cardiomyocyte calcium export through
the Na/Ca exchanger (NCX; [10]) and plasmalemmal Ca2+ ATPase
(PMCA; [11,12]), terminates contraction [13]. Physical proximity be-
tween cardiomyocyte mitochondria and SR is enforced in the same
way that proximity between individual sardines is assured in a can,
they are conﬁned in groups within a highly ordered compacted struc-
ture. This arrangement ensures an ample supply of mitochondrial ATP
to power SR calcium reuptake pumps andmay provide ameans where-
by mitochondria sense increased SR calcium release that presages in-
creased cardiac contraction. Mitochondrial sensing of cytosolic Ca2+
released from the SR stimulates an anticipatory increase in ATP produc-
tion to fuel the impending greater workload, thus preventing the ener-
gy deﬁcit that would otherwise occur after acutely increased ATP
consumption [14].
The paradigm described above is consistent with a static cardio-
myocyte subcellular architecture in which organelle interactions
are dictated by physical proximity, the “sardines in a can” model
(Fig. 1). Sarcomeric myoﬁlaments run the length of cardiac myocytes
with ribbons of mitochondria interspersed between, and the SR exists
as an intercalated network surrounding myoﬁlaments and mitochon-
dria like ﬁsh net stockings. This model contrasts with that described
for neurons, in which individual mitochondria are widely dispersed
and are transported from the cell body along the axons to the synap-
se, and perhaps back again [15]. During the course of their axonal
journeys, neuronal mitochondria transiently link to and fuse with
other mitochondria in cycles of tethering, fusion, and ﬁssion that
promote organelle regeneration through exchange of internal mito-
chondrial contents [16]. Indeed, the molecular and biophysical mech-
anisms for mitochondrial fusion and ﬁssion have been elucidated
in detail in neurons, ﬁbroblasts, and other cell types, as described in
other articles within this compendium. Until recently however
(when results of studies that manipulated mitochondrial fusion pro-
teins in mouse and fruit ﬂy hearts suggested otherwise, vide infra),
it was generally assumed that the unique subcellular architecture
and apparent absence of mitochondrial mobility in adult cardiac myo-
cytes either precluded, or obviated the need for, mitochondrialtethering, fusion and ﬁssion [17]. Here, we review new ﬁndings that
have altered the perception that cardiac mitochondria are static, ex-
ploring the evidence for and roles of mitochondrial dynamics in nor-
mal and diseased hearts.
2. The machinery of mitochondrial fusion/ﬁssion
The striking morphometric diversity of mitochondria has been
recognized for over a century. Indeed the word “mitochondrion” is
widely reported to refer to this morphological heterogeneity as it is
derived from the Greek words “mitos” (thread) and “khondros”
(grain or granule), which would seem to represent different observed
organelle shapes [18]. However, in medical parlance “chondros” pri-
marily refers to cartilage, and the term “mitochondria” was ﬁrst
used in 1898 by Carl Benda who postulated that the many microscop-
ic intracellular structures he detected by light microscopy acted like
posts or pillars to support and maintain the cell's overall size and
shape. Accordingly, he called these presumed cytoskeletal structures
mitochondria, or “threads of cartilage”. Subsequent advances in optics
and biochemistry and the development of live-cell microscopy led to
the realization that mitochondria were cellular power supplies,
correcting this functional misconception. In 1914 Lewis and Lewis
discovered mitochondrial dynamism, describing cycles of mitochon-
drial fusion and ﬁssion in various cultured chick embryo tissues
[19]: “We ﬁnd in the living (cells) that (mitochondria) can be seen
to fuse together into rods or chains, and these to elongate into
threads, which in turn anastomose with each other and may unite
into a complicated network, which in turn may again break down
into threads, rods, loops and rings.” Mitochondrial mobility, fusion
and ﬁssion have since been observed in almost every species (from
yeast to human) and cell type except adult cardiac myocytes. Mito-
chondrial ﬁssion is seen in neonatal cardiac myocytes and various im-
mortalized cardiomyocyte-like cells undergoing apoptosis [20–24].
However, cultured neonatal cardiomyocytes have a much less struc-
tured internal architecture than adult cardiomyocytes, entirely unlike
the highly organized “sardine can” design described above. Indeed,
there are no published direct observations of mitochondrial fusion
or ﬁssion in normal adult cardiac myocytes. Speciﬁc attempts to
detect mitochondrial fusion in adult cardiomyocytes using live-cell
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ﬁssion was seen only in NB HL-1 cells but not in adult cardiomyo-
cytes” [23]. Nevertheless, the past year has seen publication of
compelling genetic evidence indirectly supporting not only the occur-
rence of, but the necessity for, mitochondrial fusion/ﬁssion in adult
invertebrate and mammalian hearts [25,26]. In this context, here I
will brieﬂy review the molecular machinery of mitochondrial dynam-
ics as elucidated in non-cardiac systems, so that the discussion of
various genetic and pharmacological interrogations of cardiac mito-
chondrial fusion and ﬁssion factors that follows is readily understood.
2.1. What is the evidence that mitochondrial fusion/ﬁssion
are necessary?
Essential roles for mitochondrial fusion and ﬁssion in basic cellular
and organism function were revealed using genetic interruption of
the fusion/ﬁssion cycle. Organism-wide suppression of the Drosophila
outer mitochondrial membrane (OMM) fusion factor MARF (mito-
chondrial assembly regulatory factor, also called dMFN) induces le-
thality at the ﬂy larval stage, approximately 2–3 days after hatching
(2nd instar larvae) [25]. Likewise, genetic ablation of either of the
mammalian OMM fusion factors mitofusin (Mfn) 1 or 2, or the mito-
chondrial ﬁssion factor dynamin-related protein 1 (Drp1, a.k.a. Dlp-
1), induces embryonic lethality in mice [27,28]. Our own experience
with mitochondrial fusion-deﬁcient murine embryonic ﬁbroblasts
derived from David Chan's SV40 transformed Mfn1/Mfn2 double
null mouse embryos [29] suggests that, while fusion-defective cells
are viable with highly fragmented mitochondria, their doubling rate
is 3–4 fold slower than either wild-type or single Mfn1 or Mfn2
knockout cells. Thus, normal cell viability and both invertebrate and
vertebrate development require mitochondrial fusion/ﬁssion.
There are several consequences of normal mitochondrial fusion/
ﬁssion that may be necessary to maintain cellular and organism ho-
meostasis. Mitochondria are unique among cellular organelles in
that they possess their own genomes (mtDNA), encoding proteins es-
sential for mitochondrial biogenesis and respiratory function [30,31].
Because a normal and pathological byproduct of mitochondrial respi-
ration is reactive oxygen species (ROS) that can damage DNA, and
DNA repair mechanisms in mitochondria are imperfect compared to
those in the nucleus, the rate of accumulation of mitochondrial geno-
mic mutations is higher than that of nuclear genes. The overall prev-
alence of mtDNA mutations therefore increases over time and with
age [32]. One of the mechanisms for correcting mtDNA mutations is
through complementation of genomes exchanged through the fusion
of different organelles. Disruption of mitochondrial fusion in mouse
skeletal muscle through combined tissue-speciﬁc ablation of Mfn1
and Mfn2 increased the number of mtDNA mutations, decreased mi-
tochondrial mass, and caused cellular respiratory dysfunction [33].
Mitochondrial fusion/ﬁssion may also play a broader role in mito-
chondrial regeneration and quality control by promoting exchange
of proteins and lipids in addition to mtDNA [34]. Thus, the functional,
genetic, and structural integrity of a cell's mitochondrial population
requires cycles of organelle fusion and ﬁssion.
As ﬁssion/fusion coupled to selective elimination of damaged
daughter organelles can protect the mitochondrial pool from cumula-
tive effects of senescence and degeneration [35], it has been postulat-
ed that mitochondrial dynamics is mechanistically linked to the
process of mitophagy. A detailed description of mitophagy, the term
coined to describe selective degradation of mitochondria via autophagic
mechanisms [36], is beyond the scope of this review and can be accessed
elsewhere [37]. It is worth noting here that interfering with nor-
mal mitochondria-endoplasmic reticulum tethering by suppressing
Mfn2 (see below) prevented autophagy that is normally induced
by starvation in cultured cancer cells [38], and that disturbances in
mitochondrial ﬁssion/fusion and mitophagy contribute to the pathology
of Alzheimer's disease and other neurodegenerative syndromes [39].Mitophagy has also been implicated in heart disease [40], and factors
that mediate mitochondrial fusion and ﬁssion are ubiquitinated by the
same events that target damaged mitochondria for mitophagic
elimination [41–43]. However, delineation of causal mechanisms linking
disturbances in cardiomyocyte mitochondrial dynamics to mitophagic
dysfunction must await the results of ongoing experimentation.
2.2. What are the essential components of mitochondrial ﬁssion
and fusion?
No matter their size, shape, or cell type of origin, mitochondria are
double-membrane delimited organelles. The outer mitochondrial
membrane (OMM) contains the organelle, separating its contents
from the cytoplasm (think of an egg shell). The convoluted inner mi-
tochondrial membrane (IMM) separates the internal organelle into a
central core or matrix (egg yolk) and an inter-membranous space
(egg white). This segregated structure is essential for compartmental-
ization of the many mitochondrial enzyme complexes necessary for
oxidative phosphorylation and ATP generation, but vastly complicates
mitochondrial fusion. Further extending the egg metaphor, combin-
ing the contents two eggs while maintaining the original egg white/
yolk internal structure requires a sequential process in which the
two whites are ﬁrst merged, and then (within the double-yolk giant
egg), the two yolks are combined. Mitochondria fuse in a similar
manner. First, two mitochondria become physically connected while
retaining their individuality (“tethered” is the preferred term for
two organelles physically linked, but not exchanging contents). The
OMMs of the two organelles then fuse, creating a common inter-
membranous space with two distinct matrices, analogous to the
double-yolk giant egg. There is direct physical evidence for this dis-
tinct and separable phase of mitochondrial fusion in the form of
giant mitochondria in which a single (fused) OMM encompasses
two distinct matrix structures contained within their own (not-yet
fused) IMM. These bizarre organelles are produced by pharmacologi-
cal inhibition of IMM fusion in yeast and mammalian cells [44,45].
Given the sequential nature and functional distinctiveness of OMM
and IMM fusion, it is not surprising that different sets of fusion pro-
teins mediate these two phases. “Mitofusin” (Mfn) is the name given
to the family of OMM tethering and fusing proteins. A single Mfn,
called dMfn or MARF, mediates OMM fusion in somatic Drosophila
cells, whereas mammals have two largely functionally redundant
mitofusin proteins, Mfn1 and Mfn2. Vertebrate Mfns are highly con-
served across evolution, as is (to a somewhat lesser degree)Drosophila
MARF. Structurally, they share an extracellular amino terminal GTPase
domain, a ﬁrst heptad repeat, two closely approximated transmem-
brane (TM) domains, and a second heptad repeat. The ﬁrst TM domain
passes through the OMM, and the second TM does so again, giving the
Mfn molecule a ﬁshhook-like conﬁguration having both the amino
and carboxyl termini exposed to the cytosol. Because the second
heptad repeat of one Mfn molecule will interact with that of another
molecule in opposition [46], the inter-molecular interaction will
tether two mitochondria in much the same way that Velcro loops
and hooks attach to each other. These Mfn interactions can be either
homotypic (i.e. Mfn1–Mfn1 or Mfn2–Mfn2) or heterotypic (i.e.
Mfn1–Mfn2), thus providing functional overlap for fusion. According-
ly, elimination of either Mfn1 or Mfn2 from cultured cells or speciﬁc
tissues does not prevent fusion and has a relatively minor impact on
mitochondrial morphometry and function. By comparison, concomi-
tant elimination of both mitofusins induces mitochondrial fragmen-
tation due to unopposed organelle ﬁssion [26,29,33,47]. Although
neurological disease is not the focus of this essay, it must be noted
that loss-of-function mutations of human Mfn2 cause the neurode-
generative disease Charcot Marie Tooth Syndrome type 2A [48–52].
Since these disease-causing mutations are typically heterozygous,
the dysfunctional mutant Mfn2 proteins likely exert dominant nega-
tive effects on mitochondrial fusion.
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(Opa1; [53,54]), mutations of which cause dominant optic atrophy in
humans [55]. As beﬁts its function in IMM fusion, Opa1 is located on
the IMMwhere it also regulates cristae structure independent of organ-
elle fusion [56]. Like Mfn deﬁciency, suppression or genetic ablation of
Opa1 prevents mitochondrial fusion. Unlike mitochondrial fragmenta-
tion induced by mitofusin deﬁciency, which is the consequence of pre-
venting the initial step in the fusion process, Opa1 deﬁciency produces
bothmitochondrial fragmentation (presumably the products of repeat-
ed cycles of organelle ﬁssion without normal fusion) and unusually
large organelles containing multiple unfused internal matrix compart-
ments (the products of partial fusion [25,57,58]).
Compared to mitochondrial fusion, which requires sequential
merging of OMM and then IMM by different families of GTPases, mi-
tochondrial ﬁssion seems to be a less complex monophasic process.
Returning to the egg analogy, slicing a boiled egg into two halves re-
tains the overall egg white/egg yolk structure. This is pretty much
what occurs at a molecular level for mitochondrial ﬁssion: Individual
mitochondria are ligated and separated by a molecular garrote
formed by self-assembled oligomers of another GTPase, Drp1/Dlp1
(dynamin-related or dynamin-like protein 1) [59]. The precise molec-
ular events mediating mitochondrial ﬁssion are incompletely under-
stood, but involve translocation of cytosolic monomeric Drp1/Dlp1
to the mitochondria, its oligomerization, and GTP-driven constriction.
Activated Drp1/Dlp1 binds to the scaffolding protein Fis1 on the OMM
[60]; Fis1 may direct sub-organelle localization of the forming Drp1/
Dlp1 oligomer to the mitochondrial constriction site. GTP-binding to
Drp1/Dlp1 (in exchange for GDP) alters its molecular conﬁguration,
creating tight spirals that, working in concert, constrict the organelle
in the same way that prototypical dynamin works as a GTP-driven
molecular motor [61,62]. Consistent with this molecular model, ge-
netic ablation of mouse Drp1/Dlp1 induces mitochondrial elongation
as a result of unopposed mitochondrial fusion [28].
3. Experimental evidence that mitochondrial fusion/ﬁssion is
essential to normal hearts
As noted above, mitochondrial fusion and ﬁssion have never been
directly observed in adult cardiac myocytes. Indeed, the author is not
aware that mitochondrial fusion and ﬁssion have been observed in
normal skeletal muscle, which shares with cardiac muscle a highly or-
dered mitochondrial and myoﬁlament subcellular architecture, high
mitochondrial content, and high metabolic demands. Nevertheless,
it is accepted that mitochondrial fusion and ﬁssion not only occur in
skeletal muscle, but that these are regenerative processes critical to
maintaining normal mitochondrial morphometry and function essen-
tial for muscle homeostasis. These conclusions derive largely from the
results of tissue-speciﬁc manipulation of Drosophila and mouse mito-
chondrial fusion genes: The Drosophila mitochondrial fusion proteins
MARF/dMfn and Opa1 can be efﬁciently suppressed in a tissue-
speciﬁc manner using RNAi, inducing mitochondrial fragmentation
in skeletal (wing) muscle [57]. A similar picture of mitochondrial
fragmentation associated with myasthenia, muscle atrophy, and pre-
mature lethality was subsequently induced by combined Mfn1 and
Mfn2 gene ablation in mouse skeletal muscle [33]. These results
show that interrupting mitochondria fusion in skeletal muscle of
both invertebrates and mammals is deleterious to muscle function.
We undertook an analogous approach to answer the question of
whether mitochondrial fusion occurs in and is essential to the normal
functioning of hearts. The ﬁrst examination of mitochondrial fusion in
working heart used the same Drosophila MARF RNAi and Opa1-RNAi
pUAS transgenic lines described above for the mitochondrial studies
in skeletal muscle [57], but we suppressed the mitochondrial fusion
proteins by driving RNAi expression using a cardiomyocyte-speciﬁc
tinman promoter (tincΔ4-gal4). The Drosophila tinman gene is analo-
gous to mammalian Nkx2.5 in that it directs cardiomyocytespeciﬁcation and differentiation; its promoter therefore drives trans-
gene expression in a highly cardiomyocyte-speciﬁc manner [63]. By
breeding fruit ﬂies carrying the tincΔ4-gal4 driver with either a
pUAS-MARF RNAi or a pUAS-OPA1 RNAi, we suppressed mitochon-
drial fusion speciﬁcally in cardiac myocytes of ﬂy heart tubes.
3.1. Results from genetically-manipulated Drosophila heart models
There was little precedent for our use of Drosophila to examine the
need for mitochondrial fusion in functioning hearts. The Drosophila
heart tube is a linear structure without the complex multi-chamber
and valve morphology of vertebrates. Nevertheless, at the cellular
and tissue levels Drosophila and mammalian myocardium are strik-
ingly similar, and much has been learned about mammalian heart de-
velopment and function from research performed in fruit ﬂies [64].
Accordingly, we further miniaturized the same types of procedures
routinely used to evaluate cardiac phenotypes in genetic mouse
models (which were in turn adapted from clinical evaluation of
human cardiomyopathy). Experimental endpoints in mouse cardiac
studies typically include: 1. Non-invasive echocardiographic or path-
ological assessment of cardiac remodeling assessed as chamber
dimension at end diastole (larger end diastolic dimensions show
cardiac dilatation and indicate pathological remodeling); 2. An as-
sessment of cardiac pump performance, typically as fractional ven-
tricular shortening (the percent difference in chamber dimension
between systole and diastole; a higher value is better and a lower
value suggests cardiomyopathy); and 3. Histological and/or ultra-
structural assessment of myoﬁbril and cardiomyocyte integrity. The
Drosophila heart tube has a short axis dimension of ~150 μm, far too
small to be resolved by ultrasound. However, real-time laser imaging
of contracting Drosophila heart tubes had been described by Rolph
Bodmer using optical coherence tomography (OCT) [65], and we
found that a commercially available OCT microscope (Michelson Di-
agnostics, UK) provided excellent images of Drosophila heart tubes
with a resolution of 4 μm (Fig. 2a). Using OCT we observed that
cardiomyocyte-speciﬁc suppression of either MARF/dMfn or Opa1 in-
duced dilated cardiomyopathy, deﬁned as increased diastolic cham-
ber dimension and reduced fractional shortening [25] (Fig. 2b). We
took advantage of the ability to simultaneously drive multiple trans-
genes in Drosophila to interrogate cardiomyocyte organelle structure
with genetically-encoded green ﬂuorescence proteins (GFP) that spe-
ciﬁcally localized to and decorated mitochondria (mito-GFP) or sarco-
plasmic reticulum (SR-GFP). Cardiomyocyte mitochondria in normal
heart tubes were rounded, homogenous in size, and arranged in the
typical inter-myoﬁbrillar lanes. MARF/dMfn-deﬁcient heart tubes
showed evidence of unopposed mitochondrial ﬁssion, with prolifera-
tion of very small mitochondria and striking heterogeneity of mito-
chondrial size. Mitochondria of Opa1-deﬁcient heart tubes also
showed evidence of fragmentation, but these tiny organelles were ac-
companied by many abnormally large mitochondria as described in
Opa1-null MEFS (likely representing organelles that have undergone
outer membrane fusion without inner membrane fusion) [58]. The ar-
chitecture of calcium-containing cardiomyocyte SR was not altered in
the MARF/dMFN or Opa1 RNAi cardiomyocytes. Together, these re-
sults indicate that inhibition of mitochondrial fusion in cardiomyo-
cytes by suppression of either the critical OMM or IMM fusion
protein is sufﬁcient to induce dilated cardiomyopathy.
We tested the translatability of the Drosophila heart tube results
by investigating functional overlap between fruit ﬂy MARF/dMfn
and the human Mfn proteins. Transgenic Drosophila lines expressing
human Mfn1 or Mfn2 were created and crossed onto the cardiomyo-
pathic MARF-RNAi ﬂy. Whereas simple human Mfn overexpression
had no detectable effect on normal heart tube dimension or function,
expression of either hMfn1 or hMfn2 on the MARF/dMfn RNAi back-
ground rescued both the characteristic dilated cardiomyopathy and
mitochondrial fragmentation. The human mitofusins did not,
Fig. 2. Optical coherence tomography of normal and mitochondrial fusion-defective Drosophila hearts. A. Representative images of a fruit ﬂy heart tube in cross section (left), one iso-
lated mouse cardiac myocyte (middle) and human epidermal sweat glands (right), each acquired under the same conditions. Scale bar is 200 μm. B. Line-scan images of represen-
tative Drosophila heart tube contractions, showing chamber diameter as a function of time. Top is control ﬂy and bottom is MARF RNAi ﬂy. End-systolic and end-diastolic
dimensions (ESD and EDD) are indicated for one cardiac cycle each to the right.
Fig. 3. Mitochondrial fragmentation in mouse hearts with defective mitochondrial fusion.
Transmission electron micrograph of Mfn1/Mfn2 double null mouse myocardium 3
weeks after conditional gene ablation with tamoxifen. White arrow indicates a normal
appearing mitochondrion. Black arrows point to representative small and translucent
“fragmented” mitochondria.
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lished results). These results indicate that mammalian mitofusins
perform the same essential function as Drosophila MARF/dMfn in
the heart.
Finally, we tested whether the cardiomyopathy induced by unop-
posed mitochondrial ﬁssion might be a consequence of mitochondrial
production of toxic ROS. As the mass of a Drosophila heart tube was
not sufﬁcient for biochemical analysis of cardiomyocyte mitochondri-
al ROS production, we again used a genetic approach by expressing
superoxide dismutase (SOD1) in the MARF-RNAi ﬂy. We hypothe-
sized that SOD1 would rescue phenotypes induced by ROS, but
would not affect phenotypes induced by other factors, such as ATP
deﬁciency produced by loss of normal mitochondria. Indeed, the di-
lated cardiomyopathy conferred by MARF suppression was almost
completely normalized by concomitant expression of SOD1, whereas
mitochondrial fragmentation was incompletely rescued. This result
suggests that the cardiomyopathy caused by disrupting mitochon-
drial fusion in cardiomyocytes results in part from mitochondrial
production of toxic ROS, but that ROS are not the (only) cause of mi-
tochondrial fragmentation.
3.2. Results from genetically-manipulated mouse cardiac models
To extend our Drosophila studies to mammals and perform a more
detailed mechanistic interrogation of cardiac mitochondrial fusion,
we performed analogous genetic manipulations (i.e. cardiac-speciﬁc
ablation of the genes encoding the OMM fusion proteins, Mfn1
and Mfn2) in mice [26]. These studies used tissue-speciﬁc Cre-
recombination of the ﬂoxed allele Mfn1 and Mfn2 mice created in
David Chan's laboratory [47]. Ablating Mfn1 and Mfn2 genes with
an Nkx2.5 Cre-driver [66], which has the transcriptional characteris-
tics of the tinman Gal4 driver used in our Drosophila studies (e.g.
cardiomyocyte-speciﬁc expression beginning very early in heart de-
velopment), induced 100% lethality at approximately embryonic day
10.5. This result proves that cardiomyocyte mitochondrial fusion is
essential to normal cardiac development, but unfortunately does not
address the issue of whether mitochondrial fusion is equally impor-
tant for normal day-to-day cardiac function in adult mammals. To
answer this question, and to obtain sufﬁcient Mfn1/Mfn2 double
knockout mouse myocardium for functional, cellular, and ultrastruc-
tural analyses, we moved to a compound genetic and pharmacologi-
cal approach. The two Mfn ﬂox allele mice were crossed, and
the double ﬂox allele mice were combined with a cardiomyocyte-speciﬁc Cre transgene that expresses a modiﬁed estrogen receptor
(MER)-Cre chimeric protein only after birth (Myh6-MER-Cre-MER;
[67]), thereby avoiding any developmental effects. The MER moieties
retain the transgenic Cre in the cytosol until activated by synthetic es-
trogen receptor ligands such as tamoxifen or Raloxifene that induce
nuclear translocation. Recombination of ﬂoxed alleles is therefore
speciﬁcally induced in cardiac myocytes after systemic administra-
tion of one or the other of these two drugs. We found that mice car-
rying four ﬂoxed Mfn alleles (two for Mfn1 and two for Mfn2) and
expressing the MER-Cre-MER transgene were normal at least up to
20 weeks of age. Administration of tamoxifen or Raloxifene at
8 weeks of age induced complete cardiac-speciﬁc recombination of
a ROSA-26 lacZ reporter within 7 days; loss of Mfn1 and Mfn2 immu-
noreactivity in myocardial samples followed the same time course.
The mitochondrial ﬁssion protein Drp1/Dlp1 was not affected by
Mfn1/Mfn2 ablation, although immunoreactivity of the IMM fusion
protein Opa1 increased slightly. Thus, we created a population of
healthy adult mice in which we could interrupt the expression both
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investigations.
Achieving the conditional cardiac Mfn1/Mfn2 double knockout
mice permitted us to ask “What are the consequences of disrupting
mitochondrial fusion in situ on cardiomyocyte mitochondria, on iso-
lated cardiac myocytes, and on functioning of the integrated organ/
organism?” We started small, at the level of the mitochondria. Ultra-
structural examination revealed severe mitochondrial fragmentation
and apparent mitochondrial proliferation 3 weeks after induced
combined Mfn gene ablation (Fig. 3). Approximately 30% of the mito-
chondria appeared normal in size and crista structure (Fig. 3, white
arrow), but the majority of organelles were unusually small with
loss of the typical matrix membrane structure, manifested as varying
degrees of increased transparency (Fig. 3, black arrow). The overall
density of mitochondria was also increased. By comparison, sarco-
meric and myoﬁbrillar structures appeared healthy in the same
cells, consistent with a primary defect in mitochondrial dynamics.
The impressions obtained by transmission electron microscopic visu-
alization of a few thousand mitochondria from representative hearts
were conﬁrmed by ﬂow cytometric analysis of 30,000 isolated cardiac
mitochondria/heart. Forward scatter (directly proportional to organ-
elle size) was decreased ~40% and side scatter (inversely proportional
to organelle sphericity) was decreased by ~70%. Mitochondrial con-
tent measured as mitochondrial protein/heart mass was increased
~60% in the fusion-defective hearts, indicating mitochondrial prolif-
eration [26].
The mitochondrial morphometric abnormalities observed three
weeks after conditional combinedMfn1 andMfn2 ablation did not ob-
viously adversely impact themice, which appeared outwardly normal.
However, non-invasive echocardiographic assessment of ventricular
size and contractility revealed chamber dilatation and decreased ejec-
tion performance, suggesting subclinical cardiac dysfunction. We
therefore examined respiratory function of cardiomyocytes and mito-
chondria isolated from these hearts, compared to identically treated
controls: Succinate-stimulated whole cell respiration was only mod-
estly depressed, and both succinate and glutamate/malate-stimulated
isolated mitochondrial respiration were normal (no difference in
state3/state2 respiration between knockout and control mitochon-
dria). However, uncoupling mitochondrial respiration from ATP syn-
thesis with FCCP (think of pressing the gas pedal for respiration all
the way to the ﬂoor) uncovered defective peak respiration in Mfn1/
Mfn2 double knockout cardiac mitochondria. Taken together, these
morphometric and functional studies suggested that mitochondrial
fragmentation and degeneration induced by three weeks of combined
Mfn1/Mfn2 deﬁciency in otherwise normal adult mice compromises
peak respiration, despite mitochondrial proliferation that might be
anticipated to compensate for individual organelle dysfunction.
MER-Cre-MER-mediated cardiomyocyte gene recombination in-
duced by tamoxifen is both rapid and irreversible. Therefore, one
would expect the consequences of conditional combined Mfn1 and
Mfn2 ablation to progress. Indeed, all Mfn1/Mfn2 double cardiac
knockout mice died of apparent heart failure approximately 9 weeks
after tamoxifen treatment. Serial weekly echocardiographic studies
showed progressive cardiac enlargement with a parallel decrease in
ejection performance beginning the second week after gene ablation,
reaching levels that are not compatible with life after 6 weeks in
most mice. This disease was similar to the dilated cardiomyopathy in-
duced by MARF/dMFN suppression in Drosophila [25]. Thus, we con-
clude that mitochondrial fusion is essential in mammals not only for
cardiac development, but also for normal mitochondrial and cardiac
function.
One of the collateral beneﬁts of temporally-deﬁned tissue-speciﬁc
gene expression is the ability to interrupt cyclical phenomena such as
mitochondrial fusion/ﬁssion at equilibrium and observe the time
course of the resulting unidirectional function to calculate half-time
and cycle length for the phenomenon at steady-state. This is like apulse-chase study using in vivo gene ablation to start the clock. We
observe that mean mitochondrial size decreased by ~40% two
weeks after Mfn1 and Mfn2 were completely ablated from mouse
hearts. If one assumes that the rate of mitochondrial ﬁssion was not
affected by ablating the OMM fusion proteins, and that a ﬁssion
event produces two equally sized daughter organelles from the par-
ent, then the entire mitochondrial population had undergone (unop-
posed) ﬁssion just over two weeks after Mfn1/Mfn2 ablation. A two
week ﬁssion/fusion cycle is sufﬁciently long that it explains why di-
rect observation of mitochondrial ﬁssion and fusion in cultured cardi-
ac myocytes over a period of hours fails to detect these events [23].
4. Defective mitochondrial fusion/ﬁssion in genetic heart disease
As introduced above, human disease is linked to two naturally oc-
curring loss-of-function mutations in mitochondrial fusion proteins,
Charcot Marie Tooth Syndrome type 2A (CMT) caused by Mfn2 muta-
tions and Autosomal Dominant Optic Atrophy (DOA) caused by Opa1
mutations. Mitochondrial morphological abnormalities in the respec-
tive affected tissues are characteristic of both syndromes and are con-
sistent with impaired mitochondrial fusion. Two features of these
human diseases are notable in the current context: First, the muta-
tions are typically heterozygous, suggesting that pathology is induced
either through dominant inhibition (Mfn2) or haploinsufﬁciency
(Opa1). And second, notwithstanding the ubiquity of mitochondria
and these two mitochondrial proteins, the mutations selectively af-
fect speciﬁc tissue types (neurons and the retina, respectively), ap-
parently sparing all others. It is notable that there are no convincing
data suggesting that the heart is compromised in either CMT or in
DOA. The absence of cardiac involvement in two diseases caused by
defects in mitochondrial fusion seems to support the idea that
mitochondrial fusion and ﬁssion are dispensable for normal heart
function. There may be other reasons, however, to explain why the
heart seems to be spared in CMT and DOA, such as different fusion
protein expression levels between neurological and cardiac tissue,
variable expression of functionally overlapping proteins (i.e. Mfn1),
and different roles of mitochondrial fusion in neurons versus striated
muscle.
Mutations causing human degenerative neurological diseases
have not suggested that defective mitochondrial fusion/ﬁssion is es-
sential to cardiac health, but genetic studies of dilated cardiomyopa-
thy in the animal kingdom tell a very different story: Bovine dilated
cardiomyopathy (BDCMP) is a heritable (autosomal recessive) form
of lethal heart failure that afﬂicts young Holstein–Friesian cattle
[68–70]. Linkage analysis within affected bovine pedigrees mapped
the disease locus to chromosome 18 [71]. Subsequent ﬁne SNP map-
ping and deep resequencing identiﬁed a mutation that perfectly seg-
regated with cardiomyopathy phenotype; the mutation encodes a
premature termination codon (Q115X) in the bovine Opa3 mitochon-
drial fusion factor [72]. Functional studies uncovered decreased myo-
cardial expression of the mutant Opa3 transcript as a result of
nonsense-mediated decay, and immunoblot analysis of isolated mito-
chondria from affected cattle revealed loss of one of the two normal
Opa3 isoforms. Serendipitously, human mutations in Opa3 had been
implicated in rare Costeff optic atrophy syndrome [73] and so an
ENU-induced mouse Opa3 mutation model has been carefully pheno-
typed. Mice homozygous for the Opa3 (L122P) mutation develop (in
addition to the optic and metabolic features of Costeff syndrome)
biventricular dilatation, cardiomyocyte hypertrophy, and myocardial
ﬁbrosis. These mice succumb at approximately 4 months of age
with heart failure [74]. Thus, Opa3 mutations in cows and mice
cause cardiomyopathy.
A second, purely experimental form of dilated cardiomyopathy
further supports an essential role for mitochondrial fusion/ﬁssion in
the mammalian heart. Here, mouse ENU mutagenesis induced auto-
somal dominant dilated cardiomyopathy in a mutant line called
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ﬁed in the mitochondrial ﬁssion protein gene, Dnm1l [75]. Yeast
two-hybrid studies showed that the mutation impairs critical intra-
molecular interactions; functional studies revealed decreased mito-
chondrial ﬁssion and altered myocardial metabolism. Taken together,
these examples of inherited cardiomyopathy prove that mutational
alterations affecting mitochondrial fusion/ﬁssion can adversely im-
pact the heart.
5. Abnormal mitochondrial fusion/ﬁssion in acquired
heart disease
Mitochondrial ﬁssion occurs in, and facilitates programmed cell
death from, apoptosis [76,77]. Programmed cardiomyocyte loss plays
a signiﬁcant role in the progression from compensated hypertrophy to
overt heart failure [78–81] and in delayed tissue loss after myocardial
infarction [82]. Furthermore, failing (rat and human) hearts exhibit mi-
tochondrial fragmentation associated with decreased expression of the
IMM fusion protein, Opa1 [83]. Based on the links between mitochon-
drial ﬁssion and programmed cardiomyocyte death, it is not surprising
that there has been great interest in targeting mitochondrial ﬁssion as
a potential mediator of cardiac disease. Conceptually, there are two ap-
proaches to changing mitochondrial fusion/ﬁssion dynamics in the
heart: Enhance fusion or inhibit ﬁssion.
The ﬁrst attempt to protect cardiomyocytes from injury by enhanc-
ing mitochondrial fusion overexpressed Opa1 in cultured H9c2 cardio-
myocytes, and then assessed apoptosis after simulated ischemia-
reperfusion [83]. Although mitochondrial morphometry changed in a
manner that indicated a shift in the balance towardmoremitochondrial
fusion, there was no associated protection from ischemia-induced
apoptosis.
Two groups have tried to protect hearts from ischemia using the
reciprocal approach of inhibiting mitochondrial ﬁssion. The strongest
evidence to date supporting a causative or contributory role for in-
creased mitochondrial ﬁssion in cardiac disease was provided by
Ong, et al who used pharmacological antagonism of the mitochondri-
al ﬁssion protein Drp1 with a small molecule inhibitor, mdivi-1 (mi-
tochondrial division inhibitor-1; [84]), to rescue mouse hearts from
ischemic injury [85]. In vivo mdivi-1 treatment prior to ischemia in-
creased mitochondrial length (i.e. it attenuated ﬁssion) and reduced
myocardial infarction size by over half, compared to vehicle-treated
controls. Direct in vivo measurements of cardiomyocyte apoptosis
and programmed necrosis were not part of these experiments and it
is possible that the large systemic intravenous doses of mdivi-1 ad-
ministered (1.2 mg/kg) might have produced some effect in addition
to inhibiting mitochondrial ﬁssion. However, these results strongly
support a connection between mitochondrial dynamics and cardiac
resistance to injury.
Another recent report described beneﬁcial effects of mitochondri-
al ﬁssion inhibition induced (indirectly) by a cardiac microRNA (miR)
[86]. Here the researchers were studying transgenic mice overexpres-
sing a muscle-speciﬁc miR, miR-499, previously recognized primarily
for regulating myosin isoforms in cardiac hypertrophy [87]. They
found that increased miR-499 had few effects on normal hearts, but
that it protected against cardiomyocyte apoptosis, myocardial infarc-
tion, and post-ischemic ventricular remodeling. They had observed
Drp1 dephosphorylation and mitochondrial ﬁssion during cardio-
myocyte apoptosis, and it was previously reported that calcineurin-
modulated Drp1 phosphorylation can regulate mitochondrial ﬁssion
[88]. The authors therefore used bioinformatics to identify isoforms
of the phosphatase calcineurin A as putative miR-499 targets. They
concluded that miR-499 downregulates calcineurin, which decreases
dephosphorylated Drp1, thus preventing mitochondrial ﬁssion and
protected the heart. This rather complex chain of causality is typical
for microRNAs, which have multiple primary, secondary, and tertiary
effects on multiple direct and indirect targets [89]. However, thiscomplexity also offers the possibility that other factors may be
inﬂuencing the outcome. Indeed, two other groups have expressed
miR-499 in mouse hearts and found that, rather than being protected,
they are predisposed to heart failure [90,91]. Also, calcineurin A has
not yet been conﬁrmed as a valid in vitro target of miR-499 in myo-
cardium despite attempts to do so using genome-wide deep rese-
quencing approaches [91]. Thus, the possible collective impact of
miR-499, calcineurin A, and phosphorylated/dephosphorylated Drp1
on mitochondrial ﬁssion and cardiomyocyte apoptosis is unclear at
this time.6. Summary
The cumulative results from studies described above prove that
mitochondrial fusion/ﬁssion is essential to normal mitochondrial ho-
meostasis and necessary for normal cardiac function. Recent reports
have speciﬁcally implicated loss of mitochondrial fusion as the mech-
anism for the cardiomyopathies induced by mutation or ablation of
mammalian mitofusins and DrosophilaMARF/dMfn. These initial ﬁnd-
ings represent just the ﬁrst steps in what will certainly be a much lon-
ger journey toward a more complete understanding of the roles of
mitochondrial fusion and ﬁssion proteins play in the related functions
of cardiac bioenergetics, calcium signaling, mitochondrial quality con-
trol, and biogenesis. The ﬁeld appears well positioned to develop
greater understanding of these speciﬁc areas, and I believe an infor-
mation and insight explosion is just over the horizon.
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